[go: up one dir, main page]

WO2005079753A3 - Extended release pharmaceutical compositions of divalproex sodium - Google Patents

Extended release pharmaceutical compositions of divalproex sodium Download PDF

Info

Publication number
WO2005079753A3
WO2005079753A3 PCT/IB2005/000420 IB2005000420W WO2005079753A3 WO 2005079753 A3 WO2005079753 A3 WO 2005079753A3 IB 2005000420 W IB2005000420 W IB 2005000420W WO 2005079753 A3 WO2005079753 A3 WO 2005079753A3
Authority
WO
WIPO (PCT)
Prior art keywords
extended release
pharmaceutical compositions
release pharmaceutical
divalproex sodium
dissociating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/000420
Other languages
French (fr)
Other versions
WO2005079753A2 (en
Inventor
Pratik Kumar
Girish Kumar Jain
Ashok Rampal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2005079753A2 publication Critical patent/WO2005079753A2/en
Publication of WO2005079753A3 publication Critical patent/WO2005079753A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to an extended release formulation that includes a drug capable of dissociating into a valproate ion, from about 15% to about 50% w/w of a high viscosity grade hydroxypropyl methylcellulose, and from about 0.1% w/w of a low viscosity grade hydroxypropyl methylcellulose. The drug capable of dissociating into a valproate ion may be valproic acid and its pharmaceutically acceptable salts, esters, and amides.
PCT/IB2005/000420 2004-02-19 2005-02-18 Extended release pharmaceutical compositions of divalproex sodium Ceased WO2005079753A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN237DE2004 2004-02-19
IN237/DEL/2004 2004-02-19

Publications (2)

Publication Number Publication Date
WO2005079753A2 WO2005079753A2 (en) 2005-09-01
WO2005079753A3 true WO2005079753A3 (en) 2006-05-11

Family

ID=34878777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000420 Ceased WO2005079753A2 (en) 2004-02-19 2005-02-18 Extended release pharmaceutical compositions of divalproex sodium

Country Status (2)

Country Link
CN (1) CN1921838A (en)
WO (1) WO2005079753A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102138911B (en) * 2011-03-28 2012-12-12 孙卫东 Divalproex sodium sustained release tablets and preparation method thereof
CN105012264B (en) * 2014-04-16 2019-11-29 四川科瑞德制药股份有限公司 Sustained-release Sodium Valproate and its preparation process and purposes
CN106389368B (en) * 2015-07-29 2021-11-12 四川科瑞德制药股份有限公司 Sodium valproate sustained-release preparation and preparation process and application thereof
CN108066296B (en) * 2016-11-11 2020-11-17 南京益恒寿生命科技有限公司 Colon targeting composition containing biological active components and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019398A (en) * 1989-02-27 1991-05-28 Sanofi Pharmaceutical composition providing the sustained-release of valproic acid
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2003103635A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Extended release formulation of divalproex sodium
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019398A (en) * 1989-02-27 1991-05-28 Sanofi Pharmaceutical composition providing the sustained-release of valproic acid
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2003103635A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Extended release formulation of divalproex sodium
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QIU Y ET AL: "ONCE-A-DAY CONTROLLED-RELEASE DOSAGE FORM OF DIVALPROEX SODIUM I: FORMULATION DESIGN AND IN VITRO/IN VIVO INVESTIGATIONS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 92, no. 6, June 2003 (2003-06-01), pages 1166 - 1173, XP001161543, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
CN1921838A (en) 2007-02-28
WO2005079753A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
EP4353221A3 (en) Novel orally administrable formulation
WO2012035559A3 (en) Sustained release pharmaceutical compositions comprising pregabalin
NZ592647A (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
WO2009033131A3 (en) Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin
CA2515293A1 (en) Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
WO2011160136A3 (en) Progesterone containing oral dosage forms and related methods
MX2009014193A (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof.
PL1931316T5 (en) Controlled release pharmaceutical compositions for acid labile drugs
PH12013500173A1 (en) Oral controlled release pharmaceutical compositions of blonanserin
EP1993567A4 (en) Orally administrable gallium compositions and method of use
PE20011223A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING PEMETREXED AND AN ANTIOXIDANT SUCH AS MONOTHIOGLYCEROL, L-CYSTEINE AND THIOGLICOLIC ACID
HRP20100113T1 (en) USE OF PREPARATIONS CONTAINING A CAP-OPIOID RECEPTOR ANTAGONIST INTENDED FOR THE TREATMENT OF Dissociative Disorders
BR0311642A (en) Increased Release Sodium Divalproex Formulation
IN2015DN01738A (en)
WO2005079753A3 (en) Extended release pharmaceutical compositions of divalproex sodium
MY204440A (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
MX2012007927A (en) DP<sub>2</sub> ANTAGONIST AND USES THEREOF.
WO2003028624A3 (en) Levothyroxine compositions and methods
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
TW200727892A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
UA93355C2 (en) Formulation of suberoylanilide hydroxamic acid and method for producing same
ITMI20080798A1 (en) MODEL RELEASED COMPOSITION BASED ON DOXOFILLINA
WO2010119300A9 (en) Oral suspension of dexamethasone acetate -taste masking composition of dexamethasone
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
WO2003013441A3 (en) Levothyroxine compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200580005453.2

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 5075/DELNP/2006

Country of ref document: IN

122 Ep: pct application non-entry in european phase